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Abstract
Although the risk factor for apolipoprotein E (apoE) polymorphism in Alzheimer’s disease (AD) has been well described, the
role that apoE plays in other neurodegenerative diseases, including Pick’s disease, is not well established. To examine a
possible role of apoE in Pick’s disease, an immunohistochemical analysis was performed utilizing a novel site-directed
antibody that is specific for an amino-terminal fragment of apoE. Application of this antibody, termed the amino-terminal
apoE cleavage fragment (nApoECF) antibody, consistently labeled Pick bodies within area CA1 of the hippocampus in 4 of
the 5 cases examined. Co-localization of the nApoECF antibody with PHF-1, a general marker for Pick bodies, as well as with
an antibody to caspase-cleaved tau (TauC3) was evident within the hippocampus. While staining of the nApoECF antibody
was robust in area CA1, little co-localization with PHF-1 in Pick bodies within the dentate gyrus was observed. A quantitative
analysis indicated that approximately 86% of the Pick bodies identified in area CA1 labeled with the nApoECF antibody. The
presence of truncated apoE within Pick bodies suggests a broader role of apoE beyond AD and raises the question as to
whether this protein contributes to pathogenesis associated with Pick’s disease.
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Pick’s disease is classified as a tauopathy and is characterized by
filamentous neuronal and glial hyperphosphorylated tau [8]. Pick’s
disease is associated with severe neuronal and glial loss leading to
frontotemporal lobe atrophy [8]. Pathologically, a key feature of
Pick’s disease is the presence of Pick bodies that are composed of
aggregates of hyperphosphorylated tau [9]. Clinically, Pick’s
disease is characterized by loss of verbal skills and progressive
dementia [10]. APOE gene polymorphism is known to be
associated with Pick’s disease [11–13]. Despite this known
association between apoE and Pick’s disease, few studies have
examined apoE immunoreactivity in the Pick’s disease brain with
the exception of Hayashi et al., who demonstrated the presence of
apoE immunoreactivity in Pick bodies from two cases with the
APOE genotypes of 3/4 and 3/3, respectively [14]. To determine if
apoE is cleaved in Pick’s disease, we analyzed five cases by
immunohistochemistry using our novel, in house antibody that
detects amino-terminal cleavage fragments of apoE (termed
nApoECF antibody). We found strong immunolabeling of this
antibody within Pick bodies in the CA1 region of four of five cases
examined. In addition, co-localization of the nApoECF antibody
with PHF-1 and an antibody to caspase-cleaved tau (TauC3) was
observed. Taken together, these results demonstrate the presence
of apoE amino-terminal fragments in the Pick’s disease brain. The
high degree of co-localization between PHF-1, caspase-cleaved
tau, and our nApoECF antibody suggest a potential causal
relationship between modified tau and cleaved apoE.

Introduction
Human apoE is polymorphic with three major isoforms, apoE2,
E3, and E4, which differ by single amino acid substitutions at
positions 112 and 158 [1]. Inheritance of one copy of the APOE4
allele increases AD disease risk fourfold, while two copies raises the
risk tenfold [2]. Structurally, apoE4 is a 34 kDa protein composed
of 299 amino acids and contains two major domains, referred to as
the N-terminal (,20 kDa) and C-terminal (,10 kDa) domains,
which are connected by a short hinge region [3]. How apoE4
confers disease risk in AD is unknown, but emerging evidence
suggests that proteolytic cleavage of apoE4 may lead to a loss or
toxic-gain of function thus contributing to disease pathogenesis (for
review see [4]). Several studies have identified the presence of
,18 kDa band in human AD brain extracts, suggesting cleavage
of apoE4 near position D172 [5,6]. Previous studies have shown
that apoE4 is highly susceptible to proteolysis compared to apoE3,
and apoE4 fragments (14–20 kDa) have been identified in the AD
brain [5]. To determine if this site within apoE is cleaved by
proteases in the AD brain, we developed and characterized a sitedirected neoepitope antibody directed towards the amino-terminal
fragment that would be generated following cleavage at D172.
Application of this antibody, in situ, revealed specific localization
within NFTs that co-localized with PHF-1 in the AD brain with a
preference of localization in those AD cases with either the 3/4 or
4/4 APOE genotypes [7]. The purpose of the present study was to
examine whether amino-terminal fragments of apoE can be
documented in Pick’s disease.
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because this fragment was observed in PiD cases harboring the
APOE 3/3 genotype, these results suggest that this isoform is also
capable of undergoing fragmentation in vivo.
To determine the extent of localization of the nApoECF
antibody within Pick bodies, double-label immunofluorescence
studies were undertaken using PHF-1 as a marker for Pick bodies.
As shown using conventional immunofluorescence microscopy,
strong co-localization of the two antibodies within Pick bodies was
observed in area CA1 in Pick cases (Fig. 2A–C). The yellow/
orange color in Panel C depicts the co-localization between the
two markers. Confocal analysis confirmed the colocalization of the
nApoECF antibody with PHF-1 within Pick bodies of area CA1
(Fig. 2H–J) and at high magnification, the filamentous nature of
PHF-1 labeling was evident within Pick bodies (Fig. 2K).
As with the results utilizing bright-field, we only observed weak
labeling of the nApoECF antibody within Pick bodies located in
the dentate gyrus (Fig. 2D). This was in contrast to PHF-1, which
in addition to labeling Pick bodies in area CA1, also displayed
strong and widespread labeling of Pick bodies throughout granule
cells of the dentate gyrus (Fig. 2E and F). Therefore, based on
these results, fragmentation of apoE displayed a regional pattern of
distribution being predominantly located within the CA1 region of
the hippocampus of Pick cases. A quantitative analysis indicated
that within the CA1 region, 86% of identified Pick bodies using
PHF-1 were also labeled with the nApoECF antibody (Fig. 2G).
These results suggest that whatever aberrant processes are
responsible for generating modified tau; similar pathways may
also be involved in the fragmentation of apoE.
To determine any possible correlation between the various
groups, Pearson coefficients were determined. The Pearson
coefficient comparing nApoECF labeling alone to those Pick
bodies labeled with both PHF-1 and nApoECF was 0.23; for PHF1 alone versus nApoECF alone, 20.10; and for nApoECF and
PHF-1 versus PHF-1 alone, 20.62. These data suggest a moderate
negative correlation between the number of Pick bodies labeled
with PHF-1 alone and those labeled with both PHF-1 and
nApoECF.
In a previous report, we documented the presence of caspasecleaved TAR DNA-binding protein (TDP)-43 and caspase-cleaved
tau in Pick’s disease that revealed an almost identical staining
pattern as observed with the nApoECF antibody in the present
study. Caspase-cleaved TDP-43 and tau was found predominantly
within Pick bodies of area CA1, with little staining found in
granule cells of the dentate gyrus [15]. Therefore, we determined
the extent of co-localization of the nApoECF antibody with
caspase-cleaved tau by performing double-label immunofluorescence experiments utilizing an antibody specific for caspasecleaved tau (TauC3) [16]. Co-localization between the TauC3 and
nApoECF antibodies was observed in area CA1, with 75% of
identified Pick bodies containing caspase-cleaved tau and the
amino-terminal fragment of apoE (Fig. 3A–D). Co-localization
between TauC3 and the nApoECF antibody was also confirmed
following confocal double-label immunofluorescence experiments
(Fig. 3E–G). Interesting at high magnification, confocal analysis
revealed the punctate nature of the labeling the TauC3 antibody
(Panel H).
To determine any possible correlation between the various
groups, Pearson coefficients were determined. The Pearson
coefficient comparing nApoECF labeling alone to those Pick
bodies labeled with both TauC3 and nApoECF was 20.15; for
TauC3 alone versus nApoECF alone, 0.017; and for nApoECF
and PHF-1 versus PHF-1 alone, 20.15. These data suggest a lack
of correlation between any of the groups tested.

Results
Previous characterization of the nApoECF antibody indicated
that it is highly specific for an 18 kDa amino-terminal fragment of
apoE [7]. This in house antibody was synthesized based upon a
putative caspase-cleavage site (DADD) at position D172 of the fulllength protein. Application of this antibody to AD frontal cortex
brain sections revealed specific localization within neurofibrillary
tangles (NFTs) that was dependent upon the APOE genotype: 4/
4$3/4.3/3 [7]. However, in vitro cleavage of apoE4 by caspase-3
to generate an 18 kDa fragment detectable by the nApoECF
antibody was unsuccessful [7]. To determine if amino-terminal
fragments of apoE can be detected in Pick’s disease, an
immunohistochemical study utilizing the nApoECF antibody was
performed utilizing fixed hippocampal brain sections from five
Pick cases. Case demographics for the Pick cases used in this study
are presented in Table 1. Notice that the APOE genotype was
confirmed in 3/5 cases. All five cases had a primary neuropathological diagnosis of Pick’s disease.
As an initial step, we screened all five cases for nApoECF
immunoreactivity using bright-field microscopy. Following application of the nApoECF antibody, strong labeling of Pick bodies
within area CA1 was observed in 4/5 cases (Fig. 1A and B). A
much weaker staining pattern of Pick bodies was also observed in
granule cells of the dentate gyrus (Fig. 1C). Strong immunolabeling within area CA1 was in contrast to age-matched control
subjects, where there was a complete lack of staining within the
hippocampus (Fig. 1E). In one case (Case #5, Table 1) we did not
observe any labeling of the nApoECF antibody within Pick bodies,
but instead documented the occasional staining of apparent NFTs
(arrow, Fig. 1D). Of interest was additional screening of this case
with PHF-1, a well-known marker for Pick bodies, revealed the
complete absence of any Pick bodies in the hippocampus for this
case. Further analysis of this case by the Institute for Memory
Impairments and Neurological Disorders at the University of California, Irvine
confirmed the lack of Pick bodies within hippocampal tissue
sections. Interesting, this case did have a secondary neuropathological diagnosis of frontal temporal dementia. In any event, the
specificity of the nApoECF antibody appeared to be confined
within Pick bodies or NFTs as no other labeling was observed in
any other cell type including glial cells. A quantitative analysis of
the number of nApoECF-positive Pick bodies in area CA1
indicated a wide variability between the five cases and was highest
in two cases that were listed as having an APOE genotype of 3/3
and in which the presence of Pick bodies was confirmed (Fig. 1F).
Previous studies have shown that in vitro, apoE4 is highly
susceptible to proteolysis compared to apoE3 [5]. However,
Table 1. Case Demographics.

Case

Age

Sex

PMI

ApoE
Genotype NPD

Braak and
Braak

Plaque
Stage

1

66

F

3

N/A

PiD

Stage 0

None

2

78

M

15.37

N/A

PiD

Stage 0

None

3

63

F

6.47

3/3

PiD

Stage 0

None

4

72

M

4.5

3/3

PiD

Stage 0

None

5

63

F

3.8

3/3

PiD

Stage 0

None

6

73

F

5.1

3/3

Normal Stage 0

None

7

75

F

2.75

N/A

Normal Stage 0

None

PMI, postmortem interval in hours; NPD, neuropathological diagnosis.
doi:10.1371/journal.pone.0080180.t001
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Figure 1. Localization of an amino-terminal fragment of apoE in Pick’s disease. (A and B): Low (A) and high magnification (B) of
representative labeling from a Pick’s case (Case #4, Table 1) utilizing the nApoECF antibody illustrating staining in the CA1 region of the
hippocampus within Pick bodies. (C): Representative staining in the dentate gyrus (Case #3, Table 1) showing weaker, sparser labeling with the
nApoECF antibody. (D): Representative staining in case #5 (Table 1), which had a primary neuropathological diagnosis of Pick’s disease showing a
complete lack of labeling of Pick bodies but instead labeling of apparent NFTs (arrow). (E): Representative staining of the nApoECF antibody in an
age-matched control case revealing a complete absence of labeling. (F): Quantitative analysis of the number of Pick bodies that were nApoECFpositive for each Pick case examined with the nApoECF antibody. Data are the average of two independent counts 6S.D. For case demographics
please see Table 1.
doi:10.1371/journal.pone.0080180.g001
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Figure 2. Labeling of nApoECF antibody within the hippocampus co-localizes with PHF-1 and is regionally defined. (A–C):
Representative immunofluorescence double-labeling in Case #3 (Table 1) utilizing the nApoECF antibody (green, Panel A) and PHF-1 (red, Panel B)
revealed strong co-localization of the two antibodies within Pick bodies of area CA1 (Panel C). (D–F): In contrast to area CA1, strong
immunofluorescence was detected using PHF-1 (red, Panel E), but only weak labeling was observed within granule cells of the dentate gyrus
following application of the nApoECF antibody (green, Panel D). Panel F shows the overlap image with yellow indicating Pick bodies double-labeled
with both antibodies. (G): Quantification of Pick bodies double-labeled by PHF-1 and nApoECF. Data show the number of Pick bodies labeled with
nApoECF alone (blue bar), PHF-1 alone (green bar) or those Pick bodies that were labeled with both antibodies (red bar) in area CA1. Pick bodies were
identified in a 206 field within area CA1 by immunofluorescence overlap microscopy (n = 3 fields for 4 different Pick cases) 6S.D., *p,0.05. Data
indicated that roughly 86% of all identified Pick bodies within area CA1 were labeled with both antibodies. (H–J): Double-labeled confocal
immunofluorescence images with the nApoECF antibody (green, H), PHF-1 (red, I), and the two images overlapped (J). All scale bars represent 10 mm,
except for confocal images in Panel H–J, which represent 50 mm. (K): High magnification confocal overlapped image representing nApoECF (green
channel, left), PHF-1 (red channel, middle), and overlapped image (yellow/orange, right); notice filamentous nature of staining within the two Pick
bodies. Scale bars for Panel K represent 5 mm.
doi:10.1371/journal.pone.0080180.g002

double-label immunofluorescence experiments to determine the
extent of co-localization between TauC3 and the nApoECF
antibody. Strong co-localization between these two antibodies was
observed in over 75% of identified Pick bodies in area CA1. These
data suggest that the same processes that lead to aberrant cleavage
of tau may also be present to facilitate the cleavage of apoE.
However, it is important to note that the protease responsible for
cleaving apoE into an 18 kDa fragment that is detected by the
nApoECF antibody remains unknown. In vitro, we have previously
determined that it is not caspase-3 [7].
In summary, we have documented the presence of aminoterminal fragments of apoE3 within Pick bodies that displayed a
regional localization, and showed a high degree of co-localization
with PHF-1 and caspase-cleaved tau. These results suggest that
apoE and its’ cleavage is not restricted to AD, but may be present
in other neurodegenerative diseases. Because apoE N-terminal
fragments have been shown to be neurotoxic and can promote the
pathology associated with AD, it is interesting to speculate on
whether these fragments found in Pick bodies contribute anyway
to disease pathogenesis. Further studies examining the role of
apoE, tau and any relation to specific proteases should shed light
on whether apoE also contributes to disease pathogenesis in Pick’s
disease.

Discussion
Harboring the APOE4 allele enhances the risk for AD [2] and
several reports have suggested that it is the proteolytic cleavage of
apoE4 into neurotoxic N- and C-terminal fragments that may
provide one mechanism by which this protein contributes to AD
pathogenesis (for recent review see [4]). ApoE4 is highly
susceptible to proteolysis compared to apoE3, and apoE4
fragments (14–20 kDa) have been identified in the AD brain [5].
However, whether apoE4 or other isoforms of apoE play any role
in the etiology of Pick’s disease is currently unknown. Pick’s disease
is classified as a tauopathy that is characterized pathologically by
the presence of round Pick body structures containing hyperphosphorylated, aggregated tau [17]. Despite that APOE gene
polymorphism is known to be associated with Pick’s disease [11–
13], very few studies have examined a potential role of apoE in
Pick’s disease with the exception of Hayashi et al., who
demonstrated the presence of apoE immunoreactivity in Pick
bodies from two cases with the APOE genotypes of 3/4 and 3/3,
respectively [14]. Therefore, we sought to determine a potential
role of apoE in Pick’s disease by examining for the presence of
fragmented apoE utilizing an in house antibody designed to detect
the amino-terminal fragment of apoE [7]. In AD this antibody,
termed the amino-terminal apoE cleavage-fragment (nApoECF)
antibody, predominantly labeled NFTs in the AD brain [7].
Moreover, not only did we detect nApoECF-positive NFTs in 3/4
and 4/4 APOE genotypes, we also observed limited labeling of
NFTs in APOE 3/3 genotype cases. To perform an immunohistochemical analysis utilizing the nApoECF antibody, we examined
5 available cases of Pick’s disease in which the APOE genotype of
3/3 was identified in three of the five cases, while the APOE
genotype of the other two cases was not available (Table 1). We
predicted at the outset that we would observe very little staining
with the nApoECF antibody in those 3/3 cases based on our
previous findings in the AD brain [7], but instead observed
nApoECF staining within Pick bodies in two APOE 3/3 cases, with
the third case (Case #5) being the exception. However, further
analysis of Case #5 indicated that this case in fact did not harbor
any Pick bodies based on the lack of PHF-1 labeling and may have
instead, represented a FTD case. To our knowledge, this is the first
demonstration of fragmentation of apoE in the Pick’s disease brain
and moreover, the fragmentation occurred in cases with the APOE
genotype of 3/3.
An interesting feature of the nApoECF labeling was the regional
distribution of staining within Pick bodies specifically in area CA1
of the hippocampus. This staining pattern was in contrast to PHF1, which revealed widespread labeling of Pick bodies in both area
CA1 and also within granule cells of the dentate gyrus. This
regional staining pattern was very reminiscent of the regional
distribution pattern we previously documented for caspase-cleaved
tau and caspase-cleaved TDP-43 [15]. Therefore, we performed
PLOS ONE | www.plosone.org

Materials and Methods
Immunohistochemistry
Autopsy brain tissue from five neuropathologically confirmed
Pick cases were studied. Case demographics are presented in
Table 1. Fixed hippocampal tissue sections used in this study were
provided by the Institute for Memory Impairments and Neurological
Disorders at the University of California, Irvine. Free-floating 40 mmthick sections were used for immunohistochemical studies as
previously described [18]. No approval from Boise State University Institutional Review Board was obtained due to the exemption
granted that all tissue sections were fixed and received from
University of California, Irvine. Sections from the hippocampus
were selected for immunohistochemical analysis.
For single labeling, all sections were washed with 0.1 M Trisbuffered saline (TBS), pH 7.4, and then pretreated with 3%
hydrogen peroxide in 10% methanol to block endogenous
peroxidase activity. Sections were subsequently washed in TBS
with 0.1% Triton X-100 (TBS-A) and then blocked for thirty
minutes in TBS-A with 3% bovine serum albumin (TBS-B).
Sections were further incubated overnight at room temperature
with the nApoECF antibody (1:100). Following two washes with
TBS-A and a wash in TBS-B, sections were incubated in antirabbit or mouse biotinylated anti-IgG (1 hour) and then in avidin
biotin complex (1 hour) (ABC, Elite Immunoperoxidase, Vector
Laboratories, Burlingame, CA, USA). The primary antibody was
visualized using brown DAB substrate (Vector Laboratories).
5
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Figure 3. Co-localization of the nApoECF antibody with caspase-cleaved tau. (A–C): Representative immunofluorescence double-labeling
in Case #4 (Table 1) within the CA1 region of the hippocampus in Pick’s disease utilizing the nApoECF antibody (green, Panel A), caspase-cleaved tau
(red, Panel B) and with the overlap image shown in Panel C. All scale bars represent 10 mm. (D): Quantification of Pick bodies double-labeled by
TauC3 (caspase-cleaved tau) and nApoECF in area CA1 of the hippocampus. Data show the number of Pick bodies labeled with nApoECF alone (blue
bar), Tauc3 alone (green bar) or those Pick bodies that were labeled with both antibodies (red bar). Pick bodies were identified in a 206 field within
area CA1 by immunofluorescence overlap microscopy (n = 3 fields for 4 different Pick cases) 6S.D., *p,0.05. Data indicated that roughly 75% of all
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labeled Pick bodies within area CA1 were co-localized with both antibodies. (E–G): Double-labeled confocal immunofluorescence images with the
nApoECF antibody (green, E), PHF-1 (red, F), and the two images overlapped (G). (H): High magnification confocal overlapped image representing
nApoECF (green channel, left), TauC3 (red channel, middle), and overlapped image (yellow/orange, right). Scale bars in Panel H represent 5 mm.
doi:10.1371/journal.pone.0080180.g003

550 nm for the detection of the nApoECF antibody (green
channel, Alexa Fluor 488) and 550–600 nm for both the detection
of PHF-1 (red channel, Alexa Fluor 555) and TauC3 (red, Alexa
Fluor 555). All images displayed are 2-D, maximal intensity
projections generated acquired Z-stacks. Single plane images were
acquired with a 636 Plan-Apochromat oil-immersion objective
(NA 1.4) with emission long pass of 505 nm for the detection of the
nApoECF antibody (green channel, Alexa Fluor 488) and 550–
600 nm for the detection of TauC3 (red channel, Alexa Fluor
555).

Immunofluorescence Microscopy
Immunofluorescence studies were performed by incubating
sections with primary antibodies overnight at a room temperature,
followed by secondary anti-rabbit or mouse biotinylated anti-IgG
(1 hour) and then in ABC (1 hour). Primary antibodies utilized
included the nApoECF (1:100), PHF-1 (mouse monoclonal,
1:1,000) and TauC3 (mouse monoclonal, 1:100). The TauC3
antibody was purchased from Millipore (Billerica, MA), while
PHF-1 was a generous gift from Dr. Peter Davies (Albert Einstein
College of Medicine, Bronx, NY). For immunofluorescence colocalization studies, antigen visualization was accomplished using
an Alexa fluor 488-labeled tyramide (green, Ex/Em = 495/519)
for one label and streptavidin Alexa fluor 555 (red, Ex/Em = 555/
565) for the second label, both from Invitrogen (Carlsbad, CA).
For microscopic observation and photomicrography of the DABlabeled and fluorescent sections, an Olympus BX60 microscope
with fluorescence capability equipped with a MagnaFire SP
software system for photomicrography was employed. The
fluorescent molecules were excited with a 100-W mercury lamp.
Fluorescent-labeled molecules were detected using a filter set
having a 460–500-nm wavelength band pass excitation filter, a
505-nm dichroic beam splitter, and a 510–560-nm band pass
emission filter.

Statistical analysis
To determine the percent co-localization, a quantitative analysis
was performed as described previously [7,18] by taking 206
immunofluorescence, overlapping images from three different
fields in area CA1 in four separate Pick cases. Capturing was
accomplished by using a 2.56 photo eyepiece, and a Sony high
resolution CCD video camera (XC-77). As an example, to
determine the percent co-localization between nApoECF and
PHF-1, photographs were analyzed by counting the number of
nApoECF-, PHF-1-positive Pick bodies alone per 206 field for
each case, and the number of cells labeled with both PHF-1 and
nApoECF. Data are representative of the average number (6S.D.)
of each antibody alone or co-localized with both antibodies in each
206 field (3 fields total for 4 different cases). Statistical differences
in this study were determined using Student’s two-tailed T-test
employing Microsoft Office Excel. To determine any possible
correlations between the various groups, Pearson’s coefficients
were determined using Microsoft Office Excel.

Confocal microscopy
For confocal immunofluorescence imaging, the primary antibodies were visualized with secondary antibodies tagged with
either Alexa Fluor 488 or Alexa Fluor 555 (Invitrogen, Carlsbad,
CA.) Images were taken with the Zeiss LSM 510 Meta system
combined with the Zeiss Axiovert Observer Z1 inverted microscope and ZEN 2009 imaging software (Carl Zeiss, Inc., Thornwood, NY). Confocal Z-stack and single plane images were
acquired with an Argon (488 nm) and a HeNe (543 nm) laser
source. Z-stacks images were acquired using a 206 PlanApochromat (NA 0.8) objective, emission band passes of 505–
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